Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

July 31, 2013

Conditions
Prostate CancerNeoplasm Metastasis
Interventions
DRUG

MDX-010

selected dose administered IV every 3 weeks

Trial Locations (14)

10021

Memorial Sloan-Kettering Cancer Center, New York

11818

The Angeles Clinic and Research Institute, Los Angeles

28078

Carolina BioOncology Institute, Huntersville

48126

Henry Ford Medical Center-Fairlane, Dearborn

48183

Josephine Ford Cancer Center-Downriver, Brownstown

48322

Henry Ford Medical Center-West Bloomfield, West Bloomfield

63110

Washington University School of Medicine, St Louis

90025

The Angeles Clinic and Research Institute, Los Angeles

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

98109

Seattle Cancer Care Alliance, Seattle

98195

University of Washington Medical Center, Seattle

06520

Yale University School of Medicine, New Haven

48202-2689

Henry Ford Hospital, Detroit

97239-3098

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY